A differential impact of mycophenolic acid, prednisolone, and tacrolimus exposure on scd30 levels in adult kidney transplant recipients

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 240-245

  Barraclough, Katherine A ^a   Staatz, Christine E ^b   Johnson, David W ^a   Gillis, David ^a   Lee, Katie J ^b   McWhinney, Brett C ^c   Ungerer, Jacobus P J ^c   Campbell, Scott B ^a   Isbel, Nicole M ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

kidney transplantation; mycophenolic acid; prednisolone; soluble CD30; tacrolimus

Indexed keywords

BASILIXIMAB; CD30 ANTIGEN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; SAMPLING; UNIVARIATE ANALYSIS; VALIDATION PROCESS;

ADULT; CD30 LIGAND; COHORT STUDIES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; PROSPECTIVE STUDIES; SOLUBILITY; TACROLIMUS;

EID: 84875139105     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31828286dd     Document Type: Article

References (34)

1. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998; 10: 457-470.
2. Bowen MA, Lee RK, Miragliotta G, et al. Structure and expression of murine CD30 and its role in cytokine production. J Immunol. 1996; 156: 442-449.
3. Zhang ZX, Yang L, Young KJ, et al. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000; 6: 782-789.
4. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology. 2006; 118: 143-152.
5. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol. 2003; 10: 267-271.
6. Wang D, Wu GJ, Wu WZ, et al. Pre-and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol. 2007; 17: 278-282.
7. Kadin ME. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol. 2000; 156: 1479-1484.
8. Susal C, Pelzl S, Dohler B, et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol. 2002; 13: 1650-1656.
9. Susal C, Dohler B, Sadeghi M, et al. Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation. 2011; 91: 1364-1369.
10. Martinez OM, Villanueva J, Abtahi S, et al. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation. 1998; 65: 1240-1247.
11. Weimer R, Susal C, Yildiz S, et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transpl. 2006; 6: 1865-1874.
12. Australia and New Zealand Dialysis and Transplant Registry. Available at: http://www.anzdata.org.au/documents/pdf/ANZDATADictionary2011Feb. pdf. Accessed October 12, 2011.
13. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transpl. 2007; 7: 518-526.
14. Brown NW, Franklin ME, Einarsdottir EN, et al. An investigation into the bias between liquid chromatography-tandem mass spectrometry and an enzyme multiplied immunoassay technique for the measurement of mycophenolic acid. Ther Drug Monit. 2010; 32: 420-426.
15. McWhinney BC, Briscoe SE, Ungerer JP, et al. Measurement of cortisol, cortisone, prednisolone, dexamethasone and 11-deoxycortisol with ultra high performance liquid chromatography-tandem mass spectrometry: application for plasma, plasma ultrafiltrate, urine and saliva in a routine laboratory. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878: 2863-2869.
16. Taylor PJ, Franklin ME, Tai CH, et al. Therapeutic drug monitoring of tacrolimus by liquid chromatography-tandem mass spectrometry: is it truly a routine test? J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 883-884: 108-112.
17. Barraclough KA, Isbel NM, Kirkpatrick CM, et al. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol. 2011; 71: 207-223.
18. Barraclough KA, Isbel NM, Franklin ME, et al. Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients. Ther Drug Monit. 2010; 32: 723-733.
19. Barraclough KA, Isbel NM, McWhinney BC, et al. Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. Eur J Clin Pharmacol. 2011; 67: 1243-1252.
20. Kuypers DR, Meur YL, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010; 5: 341-358.
21. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009; 31: 139-152.
22. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005; 14(suppl 1): s2-s8.
23. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transpl. 2003; 3: 534-542.
24. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43: 623-653.
25. Nakamura T, Lee RK, Nam SY, et al. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J Immunol. 1997; 158: 2090-2098.
26. Annunziato F, Manetti R, Cosmi L, et al. Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur J Immunol. 1997; 27: 2239-2244.
27. Choi SJ, You HS, Chung SY. Tacrolimus-induced apoptotic signal transduction pathway. Transpl Proc. 2008; 40: 2734-2736.
28. Pelzl S, Opelz G, Wiesel M, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation. 2002; 73: 3-6.
29. Pellegrini P, Berghella AM, Contasta I, et al. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol. 2003; 12: 49-61.
30. Dai Z, Li Q, Wang Y, et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest. 2004; 113: 310-317.
31. Gerli R, Bistoni O, Lunardi C, et al. Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. Rheumatology. 1999; 38: 1282-1284.
32. Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005; 44: 61-98.
33. Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med. 1996; 153: 551-556.
34. Oh U, Blevins G, Griffith C, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol. 2009; 66: 471-479.